EMA validates the marketing authorization for lung cancer drug nivolumab
MAA for nivolumab is the first completed regulatory submission for a PD-1 immune checkpoint inhibitor in this tumor type. Bristol-Myers Squibb senior vice-president and head of Oncology Development